Phase I safety data of lenalidomide, bortezomib, dexamethasone, and elotuzumab as induction therapy for newly diagnosed symptomatic multiple myeloma: SWOG S1211

Detalles Bibliográficos
Autores principales: Usmani, S Z, Sexton, R, Ailawadhi, S, Shah, J J, Valent, J, Rosenzweig, M, Lipe, B, Zonder, J A, Fredette, S, Durie, B, Hoering, A, Bartlett, B, Orlowski, R Z
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2015
Materias:
Letter to the Editor
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4558587/
https://www.ncbi.nlm.nih.gov/pubmed/26252787
http://dx.doi.org/10.1038/bcj.2015.62

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4558587/
https://www.ncbi.nlm.nih.gov/pubmed/26252787
http://dx.doi.org/10.1038/bcj.2015.62

Ejemplares similares